Amylyx Pharmaceuticals (AMLX) Stock Price, Quote, News & History | Benzinga

SPY774.94+0.01%QQQ756.43+0.03%BTC/USD85,542.80−0.24%DIA512.59+0.09%GLD379.00−0.14%TLT77.13+0.03%

Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote, News & History

AMLXNASDAQ

Trade with Public

Trade with Public

$27.78

-0.01-0.04%

Last update: Oct 5, 5:37 PM

$28.56

0.772.77%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$27.92

Close

$27.78

Volume / Avg.

941.08K / 2.30M

Day Range

$27.34 - $28.09

52 Wk Range

10.83 - 41.14

Market Cap

$3.17B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

15.75%

Days to Cover

8.64

Recent Amylyx Pharmaceuticals, Inc. News

Benzinga Bulls and Bears: Ross, Moderna, Webull

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Benzinga Senior Editor

Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today

PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.

Shivdeep Dhaliwal

Crude Oil Gains 1%; US Pending Home Sales Fall In July

US stocks fell in midday trading, with S&P 500 down 0.5% and Dow dropping 0.17%. Health care shares rose 1.6%, while tech stocks fell 2.1%.

Avi Kapoor

Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday

US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.

Avi Kapoor

Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level

Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-126.58M

Investing Cash Flow (TTM)

-78.83M

Financing Cash Flow (TTM)

196.09M

Free Cash Flow (TTM)

-126.72M

Capital Expenditure (TTM)

-140.00K

Net Change in Cash (TTM)

-9.31M

Analyst Trends and Forecast

1

Apr

1

Jun

1

Jul

7

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.24B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

14.58

Earnings Yield % (TTM)

-5.07%

Earnings Yield % (FWD)

-5.04%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.91

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$49.33M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-